Article
Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
Annals of palliative medicine - 1 Sept 2020
Long Yaling, Zhang Kai, Li Yanying, Yu Min, Zhu Jiao, Huang Meijuan
Abstract excerpt
Epidermal growth factor receptor (EGFR) L861Q mutation is a non-classical mutation, with a low incidence, poor response, and uncertain resistance mechanisms when treated by an EGFR tyrosine kinase inhibitor (EGFR-TKI). The liver is one of the most common distant organs to metastasize in nonsmall cell lung cancer (NSCLC), and achieving complete remission treatment for the liver is difficult. In this report, a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.